OKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S. Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain
23 Fevereiro 2022 - 4:00AM
OKYO Pharma ("OKYO" or the "Company") - announces issuance of U.S.
Patent No. 11,254,720 covering OKYO’s dry eye drug candidate OK-101
for use to treat ocular neuropathic pain
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF), a biotechnology
company focused on the discovery and development of novel molecules
to treat inflammatory dry eye diseases and ocular pain, today
announced that the patent entitled “Methods and Systems for
Designing and/or Characterizing Soluble Lipidated Ligand Agents”
has been issued by the United States Patent and Trademark Office
(“USPTO”) as U.S. Patent No. 11,254,720. This patent contains key
claims covering OK-101 to treat neuropathic pain.
OK-101 is OKYO’s lead pre-clinical compound and
is a novel long-acting anti-inflammatory drug candidate being
developed to treat patients with dry eye disease (DED). The drug,
planned to be administered topically, is anticipated to open human
studies with a Phase 2 clinical trial in DED patients in Q4, 2022.
OKYO successfully completed a pre-IND (Investigational New Drug)
meeting with the U.S. Food and Drug Administration (FDA) on
February 14th, 2022, regarding its non-clinical and clinical
development plans.
“The pain reducing feature of OK-101 offers the
opportunity that our drug can potentially treat neuropathic corneal
pain, a severe, chronic and debilitating disease for which there
are no approved commercial treatments currently available” said Raj
Patil, PhD, Chief Scientific Officer of OKYO. “We are also excited
about the pain-relieving potential of a dry eye drug because a
considerable number of dry eye patients suffer from ocular pain.
OK-101 could provide pain relief in addition to reducing ocular
inflammation in the millions of patients suffering from DED.”
“We have made significant progress with our
pre-IND work on OK-101 and are planning to file the IND to treat
DED in Q3/Q4 2022, followed by the commencement of a Phase 2 trial
in DED patients in Q4 2022,” said Dr. Gary S. Jacob, CEO of OKYO.
“We believe that OK-101 can provide a new way to treat DED patients
who are presently not well served by drugs currently approved for
treating dry eye disease.”
The person who arranged for the release of this
announcement on behalf of the Company was Gary S. Jacob, Ph.D.,
Chief Executive Officer of OKYO.
THIS ANNOUNCEMENT CONTAINS INSIDE
INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU
WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE
(AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON
THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS
DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC
DOMAIN.
Enquiries:
OKYO Pharma Limited |
Gary S. Jacob, Chief Executive OfficerGabriele Cerrone,
Non-Executive Chairman |
+44 (0)20 7495 2379 |
|
|
|
Optiva Securities Limited
(Broker) |
Robert Emmet |
+44 (0)20 3981 4173 |
|
|
|
RedChip Companies Inc. (Investor
Relations) |
Dave Gentry |
dave@redchip.com+1 407-491-4498 |
Notes for Editors:
About OKYO
OKYO Pharma Limited (LSE: OKYO; OTCQB: EMMLF) is
a life sciences and biotechnology company admitted to listing on
the standard segment of the Official List of the UK Financial
Conduct Authority and to trading on the main market for listed
securities of London Stock Exchange plc. OKYO is focusing on the
discovery and development of novel molecules to treat inflammatory
dry eye diseases and ocular neuropathic pain.
About OK-101
OK-101 is a lipidated chemerin peptide agonist
of the ChemR23 G-protein coupled receptor which is typically found
on immunological cells of the eye responsible for the inflammatory
response. OK-101 was earlier shown to produce anti-inflammatory
activity in mouse models of DED and is designed to combat washout
through the inclusion of the lipid ‘anchor’ contained in the drug
molecule to enhance the residence time of OK-101 within the ocular
environment. OK-101 was also shown to exhibit potent ocular
pain-reducing properties in a cutting-edge mouse model of corneal
neuropathic pain, establishing its potential to treat both ocular
pain and inflammation, two key symptoms of dry eye, with a single
drug.
About Dry Eye Disease
Dry eye disease is a multifactorial disease that results in
ocular discomfort and tear film instability that can lead to ocular
surface damage. It is often a chronic problem, particularly in
older adults, and is expected to become even more prevalent with
the aging population and increased use of digital screens such as
computers and smart phones. Despite new product approvals, dry eye
disease remains a significant unmet medical need and is one of the
leading causes for patient visits to eye care specialists. Novel
therapies that improve the signs and symptoms of dry eye disease
will be beneficial to dry eye patients.
Certain statements made in this announcement are
forward-looking statements. These forward-looking statements are
not historical facts but rather are based on the Company's current
expectations, estimates, and projections about its industry; its
beliefs; and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements.
These statements are not guarantees of future performance and are
subject to known and unknown risks, uncertainties, and other
factors, some of which are beyond the Company's control, are
difficult to predict, and could cause actual results to differ
materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders
and prospective security holders not to place undue reliance on
these forward-looking statements, which reflect the view of the
Company only as of the date of this announcement. The
forward-looking statements made in this announcement relate only to
events as of the date on which the statements are made. The Company
will not undertake any obligation to release publicly any revisions
or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of
this announcement except as required by law or by any appropriate
regulatory authority.
For further information, please visit the
Company's website at www.okyopharma.com.
Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Okyo Pharma (LSE:OKYO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024